Venus Remedies' Q4 FY 2025-26 Quarterly Results

Result Summary

• Venus Remedies Ltd reported a 44.6% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 31.0%.
• Its expenses for the quarter were up by 35.8% QoQ and 18.8% YoY.
• The net profit increased 85.7% QoQ and increased 126.1% YoY.
• The earnings per share (EPS) of Venus Remedies Ltd stood at 35.53 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Venus Remedies Ltd is a pharmaceutical company involved in the research, development, manufacturing, and marketing of pharmaceutical products. The company specializes in critical care and oncology products, providing a wide range of medications to treat cancer, infections, and other serious health conditions. Headquartered in India, Venus Remedies has established a global presence, catering to markets across Europe, Asia, Africa, and Latin America. The company has dedicated research and development facilities and has been recognized for its innovative approach in the pharmaceutical sector. Recent developments include advancements in generic drug manufacturing and expansion into new therapeutic segments, although specific details are not available within the provided data.

Revenue

In the fourth quarter of fiscal year 2026 (Q4FY26), Venus Remedies Ltd reported a total income of ₹264.35 crores, marking a significant increase from the previous quarter (Q3FY26) where total income was ₹182.78 crores. This reflects a quarter-over-quarter (QoQ) growth of 44.6%. Compared to the same quarter in the previous fiscal year (Q4FY25), where the total income was ₹201.73 crores, the company achieved a year-over-year (YoY) growth of 31.0%. This substantial increase in revenue over both periods indicates a strong performance in terms of sales and income generation during Q4FY26.

Profitability

Venus Remedies Ltd demonstrated notable profitability improvements during Q4FY26. The profit before tax (PBT) for this quarter was ₹61.61 crores, up from ₹33.47 crores in Q3FY26, which translates to an 84.1% QoQ increase. In comparison to Q4FY25, where PBT stood at ₹31.04 crores, there is a remarkable YoY increase of 98.5%. After accounting for taxes, the profit after tax (PAT) was ₹47.49 crores in Q4FY26, compared to ₹25.58 crores in Q3FY26, indicating an 85.7% QoQ rise. The YoY growth in PAT is 126.1%, as it was ₹21.00 crores in Q4FY25. Earnings per share (EPS) also saw a significant increase, reaching ₹35.53 in Q4FY26, compared to ₹19.14 in the previous quarter and ₹15.71 in the same quarter of the previous year, reflecting QoQ and YoY growth of 85.6% and 126.2% respectively.

Operating Metrics

The total expenses for Venus Remedies Ltd in Q4FY26 were ₹202.74 crores, which represents a 35.8% increase from the previous quarter's expenses of ₹149.31 crores. Compared to Q4FY25, where expenses were ₹170.69 crores, there is an 18.8% increase YoY. The tax expense for Q4FY26 was ₹14.12 crores, up 79.0% from ₹7.89 crores in Q3FY26, and up 40.6% from ₹10.04 crores in Q4FY25. These operating metrics highlight the company's cost structure and tax obligations, reflecting the operational efficiency and financial health of the business during the reported period.